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Abstract
To further understand the role of neuro-immunological
interactions in the pathogenesis of rheumatoid arthritis (RA), we
studied the influence of sympathetic neurotransmitters on
cytokine production of T cells in patients with RA. T cells were
isolated from peripheral blood of RA patients or healthy donors
(HDs), and stimulated via CD3 and CD28. Co-incubation was
carried out with epinephrine or norepinephrine in concentrations
ranging from 10-5  M to 10-11  M. Interferon (IFN)-γ, tumour
necrosis factor (TNF)-α, interleukin (IL)-4, and IL-10 were
determined in the culture supernatant with enzyme-linked
immunosorbent assay. In addition, IFN-γ and IL-10 were
evaluated with intracellular cytokine staining. Furthermore, basal
and agonist-induced cAMP levels and catecholamine-induced
apoptosis of T cells were measured. Catecholamines inhibited
the synthesis of IFN-γ, TNF-α, and IL-10 at a concentration of
10-5 M. In addition, IFN-γ release was suppressed by 10-7 M
epinephrine. Lower catecholamine concentrations exerted no
significant effect. A reduced IL-4 production upon co-incubation
with 10-5 M epinephrine was observed in RA patients only. The
inhibitory effect of catecholamines on IFN-γ production was
lower in RA patients as compared with HDs. In RA patients, a
catecholamine-induced shift toward a Th2 (type 2) polarised
cytokine profile was abrogated. Evaluation of intracellular
cytokines revealed that CD8-positive T cells were accountable
for the impaired catecholaminergic control of IFN-γ production.
The highly significant negative correlation between age and
catecholamine effects in HDs was not found in RA patients.
Basal and stimulated cAMP levels in T-cell subsets and
catecholamine-induced apoptosis did not differ between RA
patients and HDs. RA patients demonstrate an impaired
inhibitory effect of catecholamines on IFN-γ production together
with a failure to induce a shift of T-cell cytokine responses
toward a Th2-like profile. Such an unfavorable situation is a
perpetuating factor for inflammation.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterised by intense immune activation within the synovial
compartment of joints and a variety of systemic manifestations.
The inflammatory process leads to cartilage and bone destruc-
tion [1]. Although the pathophysiology of RA is not completely
understood, the abundance of T cells within the mononuclear
infiltrates of the hyperplastic synovial membrane in RA
together with the local production of T cell-derived cytokines
suggest that T cells are important in the autoimmune response
in RA [2]. According to the cytokine profiles after activation,
CD4-positive T cells are subdivided into different subclasses
termed T helper lymphocyte type 1 (Th1), Th2, and others [3].
Th1 and Th2 subsets can be viewed as the polarised
ANOVA = analysis of variance; APC = antigen-presenting cell; β2R = β2-adrenergic receptor; CCP = cyclic citrullinated peptide; CRP = C-reactive 
protein; DMARD = disease-modifying anti-rheumatic drug; ELISA = enzyme-linked immunosorbent assay; EPI = epinephrine; FCS = fetal calf serum; 
FITC = fluorescein isothiocyanate; HD = healthy donor; IFN = interferon; mAb = monoclonal antibody; MS = multiple sclerosis; NE = norepinephrine; 
PBMC = peripheral blood mononuclear cell; PBS = phosphate-buffered saline; PE = phycoerythrin; PGE2 = prostaglandin E2; PI = propidium iodide; 
PKA = protein kinase A; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; SNS = sympathetic nervous system; Th1/2 = T helper 
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accentuation of an immune reaction determining the local
cytokine milieu [3]. Importantly, Th1 cells inhibit the generation
of Th2 cells and vice versa. RA is interpreted as a disease
dominated by a Th1 response and selective accumulation of
Th1 cells within the synovial compartment [4]. Although local
Th1 cell activation is regarded as the most important mecha-
nism in enhancing inflammation during the course of RA [5],
CD8-positive T cells are supposed to play an important role in
the distinct pathology of RA as well [6].
Although the etiology of RA remains elusive, the hallmark of
the clinical course is a symmetric arthritis. Since the clinical
observation that paralysed joints in patients who had an upper
motor neuron hemiplegia or poliomyelitis were spared from the
inflammatory process [7], an important role for the nervous
system in the pathogenesis of RA has been hypothesised. It is
proposed that in rheumatic diseases a disturbed interaction of
the sympathetic nervous system (SNS) and the immune sys-
tem contributes to the pathogenic process [8]. In particular, a
dysbalance between the pro-inflammatory influence of sub-
stance P released by afferent sensory nerve fibers and the
anti-inflammatory effect of norepinephrine (NE) released by
efferent sympathetic nerve fibers is proposed in RA [9]. In
addition, chronic inflammatory diseases such as RA, juvenile
chronic arthritis, and multiple sclerosis (MS) are frequently
accompanied by clinical symptoms of altered sympathetic
activity [10,11].
The requirements for sympathetic neural interactions with lym-
phoid and accessory cells of the immune system are fulfilled
because (a) lymphoid tissue is densely innervated by the SNS,
(b) neurotransmitters are released by neural varicosities, (c)
cells of the immune system express adrenergic receptors,
mainly of the β2-adrenergic type (β2R), and (d) a robust
response of immune cells can be detected after catecho-
lamine release [12]. The physiological role of the SNS in the
generation of an immune response is not yet fully understood.
Fine-tuning of the magnitude and/or the duration of an immune
response is the most favored hypothesis. A recent study dem-
onstrates pro-inflammatory actions of the SNS during the
induction phase of adjuvant arthritis and an anti-inflammatory
role in the effector phase [13].
To further investigate the impact of catecholamines on
cytokine production of human T lymphocyte populations of
age-matched healthy donors (HDs) and patients with RA,
peripheral circulating T cells were activated and the produc-
tion of the cytokines interleukin (IL)-4, IL-10, interferon (IFN)-γ,
and tumour necrosis factor (TNF)-α was studied upon co-incu-
bation with epinephrine (EPI) or NE. In addition, signal trans-
duction of β2R was determined using cAMP as the readout
parameter.
Materials and methods
Study population and determination of disease activity
Sixteen consecutive patients with RA according to the revised
American College of Rheumatology criteria [14] and a group
of 16 age-matched healthy blood donors were included in the
study. To exclude a potential influence of therapy with disease-
modifying anti-rheumatic drugs (DMARDs) on β2R character-
istics, only patients without current DMARD therapy were
included in the study. In addition, therapy with TNF-α blocking
agents or other biologicals was not allowed. Furthermore, we
excluded patients in whom other factors were supposed to
influence β2R (that is, infectious and atopic diseases, hyper-
thyroidism or hypothyroidism, untreated hypertension, therapy
with sympathomimetics or sympatholytics, and cancer).
Patients were examined by taking history, physical examina-
tion, and laboratory findings (erythrocyte sedimentation rate,
C-reactive protein [CRP], rheumatoid factor, anti-nuclear anti-
bodies, hemoglobin, leukocytes, lymphocytes, platelets, and
creatinine). Inflammatory disease activity in RA was deter-
mined by the DAS28-3 (Disease Activity Score using 28 joints
and three variables) [15]. The clinical characteristics of
patients and control subjects are summarised in Table 1. Tests
for antibodies to cyclic citrullinated peptides (anti-CCP anti-
bodies) of nine patients with RA were available. Seven
patients with RA were positive for anti-CCP antibodies,
whereas the remaining two demonstrated a negative result.
Treatment with non-steroidal anti-rheumatic drugs or gluco-
corticoids up to 7.5 mg prednisolone equivalent per day was
allowed in the patient group (four of 16 patients with RA, range
2 to 7.5 mg prednisolone equivalent per day). Previous inves-
tigations revealed that β2R characteristics are not influenced
by corticosteroids at this dosage [16,17].
The study protocol was approved by our local ethics commit-
tee, and informed consent was obtained from all subjects
included in the study.
Table 1
Clinical characteristics of the healthy control subjects and 
patients with RA studied
Patients with RA (n = 16) Control group (n = 16)
Gender (female/male) 9/7 7/9
Age, years (range) 63 ± 4.0 (25 to 92) 53 ± 4.2 (26 to 87)
Disease duration, years 
(range)
11.4 ± 4.8 (1 to 57) n.a.
Rheumatoid factor-positive 11 n.a.
C-reactive protein (mg/ml) 35.6 ± 9 n.m.
CD4/CD8 ratio 4.4 ± 0.7 3.9 ± 0.5
DAS28-3 4.73 ± 0.44 n.a.
Data are given as means ± standard errors of the mean. DAS28-3, 
Disease Activity Score using 28 joints and three variables; n.a.; not 
applicable; n.m.; not measured; RA, rheumatoid arthritis.Available online http://arthritis-research.com/content/8/5/R138
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Separation of T lymphocytes and cell culture
Peripheral blood mononuclear cells (PBMCs) of patients with
RA and HDs were separated from peripheral venous blood by
Ficoll-Hypaque (Biochrom AG, Berlin, Germany) density gra-
dient centrifugation. CD3-, CD4-, or CD8-positive T cells were
isolated using the MACS (magnetic activated cell sorting)
technique (CD3 microbeads, CD4 and CD8 T-cell isolation
kit; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) as
described earlier [18,19]. The purity of the isolated T cells was
evaluated with flow cytometry and exceeded 95% in each
experiment. A serum-free culture medium (RPMI 1640 supple-
mented with 100 IU/ml penicillin, 100 μg/ml streptomycin, 2
mM l-glutamine, and 2% TCH defined serum supplement; MP
Biochemicals, Heidelberg, Germany) was used throughout
the study. Cells (1 × 106/cells in 2 ml culture medium) were
cultured at 37°C and 5% CO2 in a humidified atmosphere.
Mitogenic stimulation of Tcells was performed with plate-
bound anti-CD3-monoclonal antibody (mAb) (clone UCHT-1,
10 μg/ml), anti-CD28-mAb (clone 37.407.111, 2 μg/ml), and
recombinant human IL-2 (0.5 ng/ml; all from R&D Systems
GmbH, Wiesbaden-Nordenstadt, Germany). For the detection
of intracellular cytokine content, T cells were stimulated for 12
hours in the presence of 2 mM Brefeldin A (Sigma-Aldrich, St.
Louis, MO, USA). Co-incubation was carried out with EPI- and
NE-hydrochloride (10-5 to 10-11 M; Aventis-Pharma GmbH,
Frankfurt, Germany). The supposed concentrations of NE in
the vicinity of sympathetic nerve fibers in lymphoid organs and
the average plasma concentration of EPI and NE were
reported to be in the range of 10-5 and 10-9 M, respectively
[20,21]. Blocking of specific catecholaminergic effects was
carried out by parallel addition of the β-adrenergic receptor
blocker propranolol (10-5 M; Schwarz Pharma AG, Monheim,
Germany).
Determination of cytokines
In a preliminary set of experiments, the kinetic of IFN-γ and IL-
10 production was determined in six HDs and seven patients
with RA at 24, 48, or 72 hours. Both cytokines were then
determined in 16 HDs and patients with RA at 48 hours. The
synthesis of TNF-α and IL-4 was measured in six HDs and
seven patients with RA. Cell culture supernatants of stimu-
lated T cells were collected and immediately analysed or
stored frozen at -80°C until analysis. IFN-γ, TNF-α, IL-4, and IL-
10 enzyme-linked immunosorbent assay (ELISA) kits (OptEIA
Immunoassay kit) were purchased from BD Biosciences (Bec-
ton Dickinson GmbH, Heidelberg, Germany). The samples
and standards were diluted in assay diluent (phosphate-buff-
ered saline [PBS] supplemented with 10% fetal calf serum
[FCS]) and analysed in duplicate. All procedures were fol-
lowed according to the recommendations of the manufacturer.
The range of cytokine detection was as follows: IFN-γ (range
4.7 to 300 pg/ml), TNF-α (range 4.7 to 300 pg/ml), IL-4 (range
4.7 to 300 pg/ml), and IL-10 (range 7.8 to 500 pg/ml). The
intra- and interassay coefficients of variation were less than
10%.
Evaluation of cell surface antigens
Aliquots of isolated T cells were washed in PBS and stained
using anti-CD3-fluorescein isothiocyanate (FITC) (clone
UCHT-1; Dako Deutschland GmbH, Hamburg, Germany),
anti-CD8-phycoerythrin (PE) (clone B9.11; Beckman Coulter
GmbH, Krefeld, Germany), and anti-CD4-PC5 (clone 13B82;
Beckman Coulter) mAbs for 30 minutes at 4°C. T-cell purity
and the CD4/CD8 ratio were determined after a final wash
step in PBS with a FACSCalibur (BD Biosciences) and Cel-
lQuest Pro software (BD Biosciences).
Determination of intracellular cytokines
Intracellular IFN-γ and IL-10 were determined in stimulated
CD3-positive lymphocytes of five HDs and five patients with
RA as described [22]. Briefly, CD4 and CD8 were stained
with the appropriate mAb (CD4: PC5-coupled, clone 13B82;
Beckman Coulter; CD8: allophycocyanin-conjugated, clone
RPA-T8; BD Biosciences). Cells were then fixed with 2%
paraformaldehyde in PBS, permeabilised with Saponine-
buffer (PBS, 2% FCS, 0.1% Saponine; Sigma-Aldrich), and
incubated with FITC-coupled anti-IFN-γ (clone 4S.B3; BD Bio-
sciences) and PE-coupled anti-IL-10 (clone JES3-19F1; BD
Biosciences) mAbs for 30 minutes at 4°C. At least 10,000
events were counted for each experiment. IFN-γ- or IL-10-pro-
ducing cells were analysed in the CD4-positive and CD8-pos-
itive T-cell subpopulations after applying a constant gate that
was set on the respective marker. The percentage of positive
cells was determined with CellQuest Pro software, using two-
dimensional dot plots.
Determination of apoptosis
The proportion of apoptotic cells was evaluated in isolated
Tcells of five patients with RA and five HDs. T cells were stim-
ulated for 48 hours, and co-incubation was carried out with
EPI or NE (10-5 and 10-9 M). Cells were washed in Annexin
binding buffer (150 mM NaCl, 10 mM HEPES, and 2 mM
CaCl2) and stained with Annexin-V-FITC (Bender MedSys-
tems GmbH, Vienna, Austria), propidium iodide (PI), CD8-PE
(clone B9.11; Beckman Coulter), and CD4-APC (clone RPA-
T4; BD Biosciences) for 30 minutes at 4°C. The proportion of
early (Annexin-V-positive/PI-negative) and late apoptotic/
necrotic (Annexin-V-positive/PI-positive) cells was determined
in the CD4-positive and CD8-positive subpopulations, using
two-dimensional dot blots and appropriate gates.
Evaluation of basal and stimulated intracellular cAMP
Basal and stimulated levels of cAMP were determined in CD4-
positive and CD8-positive T cells (HDs, n = 8; patients with
RA, n = 5). Aliquots of 2 × 106 cells in incubation buffer (PBS,
0.5% bovine serum albumin, 250 μM ascorbic acid, and 100
μM theophylline) were incubated for 10 minutes at 37°C in a
water bath. The β2R agonist terbutaline (10-5  M; Sigma-
Aldrich) or incubation buffer was added, and the cells were
incubated for an additional 15 minutes at 37°C. Incubation
buffer was then added in excess to terminate the reaction.Arthritis Research & Therapy    Vol 8 No 5    Wahle et al.
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Cells were then lysed by the addition of 150 μl 0.1 N hydro-
chloric acid. The concentrations of baseline and stimulated
levels of cAMP in CD4- and CD8-positive T cells were deter-
mined using a cAMP ELISA (low pH; R&D Systems GmbH)
according to the guidelines of the manufacturer.
Statistical analysis
Values in the table and figures are given in means and stand-
ard errors of the mean (if not otherwise indicated). The relative
change of cytokine production upon co-incubation with cate-
cholamines was determined after defining the concentration of
the respective cytokine in the control cultures as 100% for
each patient and healthy control. A comparison of the catecho-
lamine effect on cytokine production was calculated by the
repeated measures analysis of variance (ANOVA) followed by
the Bonferroni test. When the normality test failed, the Kruskal-
Wallis test and the Dunnett's method for calculation of multiple
comparisons were used. The relative catecholamine response
values in comparison between patients with RA and controls
were first analysed by the one-way ANOVA to determine
whether an overall statistically significant change existed
before using the two-tailed unpaired Student's t test. A corre-
lation analysis between disease characteristics and cytokine
concentrations was carried out by means of Pearson product
moment or the Spearman rank order correlation. Statistically
significant differences were considered when p < 0.05.
Results
Influence of catecholamines on cytokine production by T 
cells
The preliminary experiments determining the kinetics of IFN-γ
and IL-10 production in patients with RA demonstrated an
increase of IFN-γ production in the first 48 hours in HDs (24
hours: 658 ± 221 pg/ml; 48 hours: 6,195 ± 1,920 pg/ml) and
a slight decrease thereafter (72 hours: 5,952 ± 3,030 pg/ml).
IL-10 production increased over the entire culture period (24
hours: 112 ± 38 pg/ml; 48 hours: 412 ± 179 pg/ml; 72 hours:
496 ± 155 pg/ml). Patients with RA exhibited increasing IFN-
γ (24 hours: 73 ± 10 pg/ml; 48 hours: 670 ± 242 pg/ml; 72
hours: 1,867 ± 596 pg/ml) as well as IL-10 synthesis (24
hours: 21 ± 13 pg/ml; 48 hours: 166 ± 68 pg/ml; 72 hours:
240 ± 72 pg/ml). IFN-γ and IL-10 synthesis was lower in
patients with RA compared with HDs at each time point stud-
ied (p < 0.05, two-way ANOVA). The relative influence of 10-
5 M EPI on IFN-γ production differed significantly between
patients with RA and HDs at 24 hours (patients with RA 74%
± 10%, HDs 27% ± 8% of control cultures, p < 0.01). NE or
lower concentrations of EPI demonstrated no overt differ-
ences regarding the influence on IFN-γ production. Catecho-
lamines showed no difference on IL-10 synthesis at the
different time points or between HDs and patients with RA
(data not shown).
Because the cytokine synthesis of patients with RA was very
low at 24 hours, and even further reduced by catecholamines,
final cytokine analysis was carried out at 48 hours. High con-
centrations of EPI or NE (10-5 M) significantly inhibited IFN-γ
production in HDs (baseline values of IFN-γ: HDs 3,461 ± 960
pg/ml; patients with RA 2,117 ± 568 pg/ml; p = 0.396) (Fig-
ure 1a). IL-10 synthesis was suppressed by 10-5 M EPI, but
not by NE (baseline values of IL-10: HDs 322 ± 95 pg/ml;
patients with RA 148 ± 34 pg/ml; p = 0.165) (Figure 1c,d).
Lower concentrations of catecholamines exerted no signifi-
cant effect. In patients with RA, 10-5 M EPI significantly inhib-
ited IFN-γ and IL-10 expression at 48 hours whereas NE did
not suppress cytokine production significantly (Figure 1). In
addition, the reduction of IFN-γ synthesis was significantly
lower in patients with RA upon co-incubation with 10-5 M EPI
or NE and 10-7 M EPI (Figure 1a, b). In contrast to IFN-γ pro-
duction, that of IL-10 was similarly affected by catecholamines
in HDs and patients with RA (Figure 1c,d).
IL-4 secretion of activated T cells from HDs was not influenced
by catecholamines (baseline values of IL-4: HDs 365 ± 62 pg/
ml; patients with RA 300 ± 95 pg/ml; p = 0.579) (Figure 2a,b).
In patients with RA, the IL-4 concentration in the culture super-
natant of activated T cells was suppressed by 10-5 M EPI, just
failing to reach the significance level compared with control
cultures (p = 0.055). However, the relative production of IL-4
upon the influence of 10 μM EPI was significantly lower in
patients with RA compared with HDs (p < 0.02, Figure 2a).
TNF-α synthesis was suppressed dose-dependently by cate-
cholamines. A significant inhibition was observed upon co-
incubation with 10-5 M EPI or NE in HDs and 10-5 M EPI in
patients with RA at 48 hours (baseline levels of TNF-α: HDs
3,524 ± 554 pg/ml; patients with RA 2,087 ± 432 pg/ml; p =
0.065) (Figure 2c,d). No difference was observed between
the relative inhibition of TNF-α by catecholamines in patients
with RA and HDs (Figure 2c, d). Incubation of activated T cells
with 10-5 M propranolol in parallel to 10-5 M EPI or NE antago-
nised the catecholamine effects on cytokine production (Fig-
ures 1 and 2).
Examination of the cytokine ratio of activated T cells from HDs
revealed a significant decrease in the IFN-γ/IL-10 ratio upon
co-incubation with 10-5 M EPI (Figure 3a). Likewise, the IFN-γ/
IL-4 ratio decreased upon co-incubation with 10-5 M EPI (Fig-
ure 3b). However, in patients with RA, EPI failed to induce any
shift in the IFN-γ/IL-10 or IFN-γ/IL-4 ratios (Figure 3a,b).
Influence of catecholamines on intracellular cytokine 
expression
The number of IFN-γ-producing cells was higher in the CD8-
positive compared with the CD4-positive population (HDs:
6.6% ± 1.1% CD4/IFN-γ-positive cells and 14.6% ± 2.2%
CD8/IFN-γ-positive cells, p < 0.02; patients with RA: 2.7 ± 0.3
CD4/IFN-γ-positive cells and 6.2 ± 0.4 CD8/IFN-γ-positive
cells, p < 0.001). In addition, increased numbers of CD4/IFN-
γ- and CD8/IFN-γ-positive T cells were detected in the controlAvailable online http://arthritis-research.com/content/8/5/R138
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subjects versus patients with RA (p < 0.05, Figure 3c, d).
High-dose EPI or NE (10-5 M) significantly inhibited the expres-
sion of intracellular IFN-γ in CD4- and CD8-positive T cells of
patients with RA and controls (Figure 3c, d). The inhibition of
IFN-γ expression in CD4-positive T cells did not differ between
patients with RA and controls (Figure 3c). However, the rela-
tive reduction in the number of CD8-positive/IFN-γ cells was
significantly more pronounced in HDs compared with patients
with RA (Figure 3d). Low concentrations of catecholamines
exerted no significant effect. The functional effects of 10-5 M
catecholamines could be abrogated by propranolol (Figure 3c,
d).
Influence of age and disease activity on cytokine 
production by T cells and catecholamine effects
In HDs, a significant positive correlation existed between age
and the relative concentrations of IFN-γ produced by activated
T cells after co-incubation with 10-5 M EPI (Figure 4a), indicat-
ing an age-related decline of the suppressive effect of EPI on
IFN-γ production (increased values mean less suppression). A
similar relationship was observed between the effect of EPI
upon IL-10 synthesis of activated T cells and age in HDs (Fig-
ure 4c). The correlation between age and NE effects and the
correlation between age and effects at lower concentrations
of EPI (10-7 to 10-11 M) remained non-significant (data not
shown).
Figure 1
Modulation of interferon (IFN)-γ and interleukin (IL)-10 synthesis of activated T cells by catecholamines in healthy donors (HDs) (n = 16, white bars)  and patients with rheumatoid arthritis (RA) (n = 16, gray bars) Modulation of interferon (IFN)-γ and interleukin (IL)-10 synthesis of activated T cells by catecholamines in healthy donors (HDs) (n = 16, white bars) 
and patients with rheumatoid arthritis (RA) (n = 16, gray bars). The concentrations of IFN-γ upon co-incubation with (a) epinephrine (EPI) and (b) 
norepinephrine (NE) and of IL-10 upon co-incubation with (c) EPI and (d) NE were determined in the culture supernatant by means of enzyme-linked 
immunosorbent assay after T-cell stimulation for 48 hours. The baseline values of each RA patient and HD were defined as 100%, and the cytokine 
concentrations upon co-incubation with catecholamines were expressed as percentage of baseline values. *p < 0.001 and ¶p < 0.05 denote signif-
icant differences in cytokine production of patients with RA or HDs compared with the control values. P values indicate significant differences 
between the catecholamine effects of patients with RA and HDs, respectively. PROP, propranolol.Arthritis Research & Therapy    Vol 8 No 5    Wahle et al.
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Interestingly, in patients with RA, no such correlation was evi-
dent between age and effects of EPI at the high concentra-
tions (Figure 4b, d). Additionally, no correlation was observed
between baseline cytokine values or the functional effect of
catecholamines and disease activity, disease duration, the
number of involved joints, CRP, and other laboratory values.
Furthermore, no relationship was observed between baseline
cytokine values or catecholamine effects and the CD4/CD8
ratio or the amount of corticosteroids administered.
Generation of cAMP after stimulation of β2R of T cells
Stimulation of β2R with terbutaline induced cAMP accumula-
tion in isolated CD4- and CD8-positive T cells of patients with
RA and HDs (data not shown). However, no significant differ-
ences were found regarding agonist-induced cAMP genera-
tion of T-cell subpopulations in patients with RA compared
with HDs (data not shown).
Influence of catecholamines on T-cell apoptosis
Given that catecholamines have been reported to induce
apoptosis in T lymphocytes [23], the possible influence of cell
death on cytokine production of stimulated T cells upon co-
incubation with catecholamines was tested. After stimulation
of T cells for 48 hours with anti-CD3-mAb and anti-CD28-mAb
together with IL-2, 2.3% ± 0.3% T cells went into apoptosis
(Annexin-V-positive, PI-negative) in HDs compared with 2.6%
Figure 2
Modulation of interleukin (IL)-4 and tumour necrosis factor (TNF)-α synthesis of activated T cells by catecholamines in healthy donors (HDs) (IL-4: n  = 6; TNF-α: n = 5, white bars) and patients with rheumatoid arthritis (RA) (IL-4: n = 5; TNF-α: n = 7, gray bars) Modulation of interleukin (IL)-4 and tumour necrosis factor (TNF)-α synthesis of activated T cells by catecholamines in healthy donors (HDs) (IL-4: n 
= 6; TNF-α: n = 5, white bars) and patients with rheumatoid arthritis (RA) (IL-4: n = 5; TNF-α: n = 7, gray bars). The concentrations of IL-4 upon co-
incubation with (a) epinephrine (EPI) and (b) norepinephrine (NE) and of TNF-α upon co-incubation with (c) EPI and (d) NE were determined in the 
culture supernatant by means of enzyme-linked immunosorbent assay after T-cell stimulation for 48 hours. The baseline values of each HD and 
patient with RA were defined as 100%, and the cytokine concentrations upon co-incubation with catecholamines are given as percentage of base-
line values. *p < 0.001 and ¶p < 0.05 as compared with values obtained upon stimulation in the presence of medium alone. P values indicate signif-
icant differences between the catecholamine effects of patients with RA and HDs, respectively. PROP, propranolol.Available online http://arthritis-research.com/content/8/5/R138
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± 0.5% in patients with RA (p = 0.674). The proportion of late
apoptotic/necrotic cells was 6.2% ± 0.7% in HDs and 10.3%
± 2.6% in patients with RA (p = 0.337). In the presence of 10-
5 M and 10-9 M EPI or NE, no change in the number of apop-
totic or necrotic cells was observed in HDs and patients with
RA (data not shown).
Discussion
In the present study, we determined the effects of catecho-
lamines on cytokine production of T cells from patients with
RA and HDs. In addition, cAMP generation and induction of
apoptosis after β2R stimulation were evaluated. The functional
effects of catecholamines on cytokine production demonstrate
an impaired suppression of IFN-γ production in patients with
RA together with a failure to induce a shift toward a more Th2-
like cytokine profile that is observed in HDs. Moreover, the
reduced catecholaminergic control on IFN-γ production in
patients with RA compared with HDs mainly affects CD8-pos-
itive T cells. The functional discrepancy of cytokine synthesis
in patients with RA versus HDs upon the influence of catecho-
Figure 3
Influence of catecholamines on cytokine ratios and intracellular interferon (IFN)-γ expression in healthy donors (HDs) (white bars) and patients with  rheumatoid arthritis (RA) (gray bars) Influence of catecholamines on cytokine ratios and intracellular interferon (IFN)-γ expression in healthy donors (HDs) (white bars) and patients with 
rheumatoid arthritis (RA) (gray bars). The ratios between the raw cytokine values of (a) IFN-γ and interleukin (IL)-10 (n = 16) or (b) IFN-γ and IL-4 
(HDs: n = 6; patients with RA: n = 5) were evaluated after stimulation of T cells for 48 hours with medium and 10-5 M epinephrine (EPI), respectively. 
Intracellular IFN-γ was determined in (c) CD4-positive and (d) CD8-positive T cells activated for 12 hours. The baseline values of IFN-γ-positive cells 
in the CD4 and CD8 T-cell populations of each RA patient and HD were defined as 100%, and the number of IFN-γ-positive cells upon co-incuba-
tion with catecholamines related to the baseline values of each HD and patient with RA. *p < 0.05 as compared with the values obtained upon con-
trol conditions. NE, norepinephrine; PROP, propranolol.Arthritis Research & Therapy    Vol 8 No 5    Wahle et al.
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lamines is cytokine-specific. Whereas the production of IFN-γ
is inhibited to a lesser extent in patients with RA, the catecho-
laminergic influence on IL-10 and TNF-α is unaffected. Other-
wise, a catecholamine-induced suppression of IL-4 production
by T cells is observed only in patients with RA.
Catecholamines regulate cytokine expression depending on
the cytokine studied, the cell type, and the experimental condi-
tions used. In general, the production of Th1 (type 1) cytokines
and TNF-α is inhibited, whereas Th2 (type 2) cytokines are
slightly suppressed, unchanged, or even induced by
catecholamines (reviewed in [24]). However, under conditions
promoting Th1 development (that is, stimulation in the pres-
ence of IL-12), it could be demonstrated that high doses of NE
(10 μM) increase expression of the prototypic Th1 cytokine
IFN-γ in CD4-positive T cells [25].
Figure 4
Correlation between age and epinephrine (EPI) effects in patients with rheumatoid arthritis (RA) and healthy subjects Correlation between age and epinephrine (EPI) effects in patients with rheumatoid arthritis (RA) and healthy subjects. The age of the subjects was 
plotted against concentrations of the relative interferon (IFN)-γ in (a) healthy donors (HDs) and (b) patients with RA and of interleukin (IL)-10 in (c) 
HDs and (d) patients with RA after co-incubation of activated T cells with 10-5 M EPI for 48 hours. The baseline values of each HD and patient with 
RA were defined as 100%. (Concentrations are presented in Figure 1 legend.) The cytokine concentrations upon co-incubation with 10-5 M EPI are 
given as percentage of baseline values. p, the p value; r, the respective correlation coefficient.Available online http://arthritis-research.com/content/8/5/R138
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Little is known about the impact of catecholamines on cytokine
production in patients with RA. A comparable increase of IFN-
γ-producing lymphocytes in peripheral blood was induced by
EPI infusion in patients with RA and HDs [26]. The recruitment
of IFN-γ-producing lymphocytes into the periphery rather than
a true increase in cytokine synthesis by EPI has been pro-
posed [26]. In contrast, the number and EPI-induced increase
of IL-10-positive monocytes were higher in patients with RA
compared with HDs [26]. After induction of mental stress by
public speaking, a significant increase of IFN-γ production
upon stimulation of PBMCs with phytohaemagglutinin was
detected in HDs but not in patients with RA [27]. Suppression
of TNF-α synthesis by the β2R agonist terbutaline was higher
in lipopolysaccharide-stimulated PBMCs of patients with RA
in vitro [28]. In the collagen type II-induced arthritis model of
mice, chemical sympathectomy before the induction of arthritis
decreased disease severity and induced the expression of IL-
4 and IL-10. In contrast, sympathectomy in the chronic phase
aggravated the inflammatory process and also resulted in an
increase in IFN-γ and TNF-α [13].
The results of our study point to a similar mechanism demon-
strating a disturbed interaction of the SNS and the immune
system. Although catecholamines shift the cytokine profile
toward a Th2-dominated cytokine environment in HDs, the
IFN-γ/IL-10 ratio or IFN-γ/IL-4 ratio does not change after co-
incubation with EPI in patients with RA. Hence, the outcome
after physiological or pharmacological β2R stimulation results
in a pro-inflammatory rather than an anti-inflammatory cytokine
environment in patients with RA [29]. A similar reduction in the
catecholaminergic control of IFN-γ expression was recently
reported in patients with MS [30]. In addition, the same study
demonstrated a restored suppression of IFN-γ expression in
patients with MS treated with IFN-β. A disruption of the β2R-
mediated suppression of IFN-γ production has been shown
after allergen provocation in patients with asthma whereas the
reactivity via prostaglandin E2 (PGE2) remained unchanged
[31].
Of interest, a highly significant correlation between age and
suppression of IFN-γ and IL-10 was observed in HDs. This
relationship was completely abrogated in patients with RA. An
accelerated aging of the immune system has been described
in RA [32]. As an example, immunosenescence in healthy sub-
jects and premature aging of the immune system in RA are
characterised by shrinkage of the T-cell receptor repertoire
and loss of costimulatory molecules such as CD28 [33]. Most
likely, the inflammatory process in RA disrupts the age-related
control of catecholamines on cytokine production. In this
respect, alterations of the autonomic nervous system, includ-
ing increased circulating NE concentrations and reduced β2R
expression, are similar in elderly people as compared with
patients with RA [33]. Consequently, the differences in the
catecholamine-controlled cytokine production can be
regarded as part of a vicious circle aggravating the inflamma-
tory process that characterises the distinct pathology of RA. It
is yet unknown whether the altered influence of catecho-
lamines on T-cell cytokine production is specific for RA or MS.
However, a comparable reduction in β2R expression on
PBMCs has been observed in RA and other chronic inflamma-
tory diseases like systemic lupus erythematosus (SLE) or
chronic inflammatory bowel disease [16,34]. Hence, it might
be suggested that the inflammatory process itself modifies
β2R function. Nevertheless, an altered influence of catecho-
lamines on cytokine production has to be interpreted in the
context of a disease-specific cytokine profile (for example,
more polarised Th1- or Th2-like reactions in RA and SLE,
respectively).
From a molecular point of view, the functional effects of cate-
cholamines on lymphocytes are induced by the accumulation
of intracellular cAMP in lymphocytes after binding to constitu-
tively expressed β2R coupled to stimulatory guanine nucleo-
tide binding proteins (Gs-proteins) [35,36]. This in turn leads
to an adenylyl cyclase-mediated cAMP increase, activation of
protein kinase A (PKA) [37], and finally to binding of the tran-
scription factor CREB (cAMP-responsive element binding
protein) to specific cAMP-responsive elements on the DNA
[38]. In the present study, β2R-mediated cAMP generation in
CD4-positive and CD8-positive T cells was similar in patients
with RA and HDs. In contrast, in PBMCs, previous investiga-
tions revealed an increased cAMP production and a higher
activity of the PKA-I and -II isoenzymes in patients with RA
[28,39]. On the other hand, B cells of patients with RA dem-
onstrated a reduced agonist-induced cAMP generation [16].
These differences in catecholaminergic cAMP generation sug-
gest that complex and cell-specific changes of β2R function
and signal transduction account for alterations of catecho-
lamine effects on lymphocyte function in RA.
The similar influence of catecholamines on TNF-α and IL-10
production in patients with RA and HDs is in agreement with
the unchanged β2R agonist-induced cAMP generation in
CD4- and CD8-positive T cells of patients with RA. An expla-
nation for the enhanced catecholaminergic influence on IL-4
synthesis in patients with RA may be found in an increased
inhibitory effect of catecholamines on IL-2 production that
decreases IL-4 synthesis indirectly [40,41]. However, T cells
were stimulated in the presence of IL-2 in our study. On the
other hand, human Th1 cells produce low levels of IL-4 [42],
and increased numbers of Th1 and Th0 cells have been
reported in the peripheral circulation of patients with RA
[43,44]. In contrast to Th2 cells, Th1 and Th0 cells express
β2R [45]. Hence, the effect of EPI on IL-4 production most
likely reflects a different T helper cell composition in the
peripheral blood of patients with RA.
In any case, the reduced functional effect of catecholamines
on IFN-γ production is explained neither by differences in
cAMP generation nor by the frequency of Th-cell subtypes inArthritis Research & Therapy    Vol 8 No 5    Wahle et al.
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patients with RA. Moreover, different functional effects of
PGE2 and isoproterenol on T-cell proliferation, regardless of
equimolar cAMP amounts generated, point to a more complex
interaction between β2R and T-cell function [46]. Use of addi-
tional β2R signaling pathways most likely accounts for the dif-
fering effects of catecholamines during the inflammatory
process in RA. These include the modulation of transcription
factor NF (nuclear factor)-κB, PKA-independent signal trans-
duction pathways like c-Jun N-terminal kinase/Src family tyro-
sine kinase Lck, MAPK (mitogen activated protein kinase), and
potassium ion channels [47-51]. Additionally, mechanisms
that control β2R reactivity apart from GRKs (G protein-cou-
pled receptor kinases) contribute to differences regarding
functional consequences upon activation of β2R [52-54].
Conclusion
In summary, we demonstrate a failure of catecholamines to
shift T-cell cytokine responses toward the expected Th2 pro-
file in patients with RA; this failure thus generates a cytokine
environment that perpetuates inflammation. The modified cat-
echolaminergic control on cytokine production is specific for
the cytokine and cell type studied, resulting in a preserved Th1
profile despite an unimpaired cAMP generation in T cells. Our
results further demonstrate that the changes of functional cat-
echolaminergic effects on cytokine production in RA originate
from various mechanisms instead of from a single cause.
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